![PDF) Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study PDF) Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study](https://i1.rgstatic.net/publication/303909646_Safety_and_efficacy_of_OvaleapR_recombinant_human_follicle-stimulating_hormone_for_up_to_3_cycles_in_infertile_women_using_assisted_reproductive_technology_A_phase_3_open-label_follow-up_to_Main_Study/links/5900adb0a6fdcc8ed50e8f30/largepreview.png)
PDF) Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to Main Study
![PDF) Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study PDF) Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study](https://i1.rgstatic.net/publication/341658347_Effectiveness_and_safety_of_follitropin_alfa_OvaleapR_for_ovarian_stimulation_using_a_GnRH_antagonist_protocol_in_real-world_clinical_practice_a_multicenter_prospective_open_non-interventional_assiste/links/5ece94f492851c9c5e5fe49b/largepreview.png)
PDF) Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
Owen Mumford Unveils New Self-Injection Pen for the Administration of Ovaleap® - Infertility Treatment
Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pen
![Plastics World on Twitter: "Owen Mumford launches Ovaleap self-injectable pen for Teva's new fertility treatment https://t.co/Llisz6PSy9 https://t.co/0xaL3coIrP" / Twitter Plastics World on Twitter: "Owen Mumford launches Ovaleap self-injectable pen for Teva's new fertility treatment https://t.co/Llisz6PSy9 https://t.co/0xaL3coIrP" / Twitter](https://pbs.twimg.com/media/CmMNtX8WAAAn80I.jpg)
Plastics World on Twitter: "Owen Mumford launches Ovaleap self-injectable pen for Teva's new fertility treatment https://t.co/Llisz6PSy9 https://t.co/0xaL3coIrP" / Twitter
![Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5427053/bin/40268_2017_182_Fig1_HTML.jpg)
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap<sup>®</sup> (XM17), Comparability with Gonal-f<sup>®</sup>, and Performance/Consistency. - Abstract - Europe PMC
![PDF) Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study PDF) Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study](https://i1.rgstatic.net/publication/350127206_Safety_of_OvaleapR_Follitropin_Alfa_in_Infertile_Women_Undergoing_Superovulation_for_Assisted_Reproductive_Technologies_A_Multinational_Comparative_Prospective_Cohort_Study/links/605f346d458515e834757412/largepreview.png)
PDF) Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pen
![Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study | Reproductive Biology Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study | Reproductive Biology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12958-016-0164-y/MediaObjects/12958_2016_164_Fig2_HTML.gif)
Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study | Reproductive Biology
![Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study | Reproductive ... Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study | Reproductive ...](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12958-020-00610-2/MediaObjects/12958_2020_610_Fig1_HTML.png)